Niska ostrość wzroku a terapia w ramach programu lekowego „Leczenie neowaskularnej (wysiękowej) postaci zwyrodnienia plamki związanego z wiekiem”
Autorzy: Małgorzata Seredyka-Burduk, Magdalena Pol, Grażyna Malukiewicz, Bartłomiej Kałużny

Low Vision and the Therapy in Drug Prescription Program “Treatment of Neovascular (Exudative) Form of Age-related Macular Degeneration”

Wydanie 2/2018
str. 22 – 25

Autorzy: Małgorzata Seredyka-Burduk 1,2 , Magdalena Pol 1 , Grażyna Malukiewicz 1 , Bartłomiej Kałużny 1.2

1 Katedra i Klinika Chorób Oczu Wydziału Lekarskiego Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu
Kierownik: prof. dr hab. n. med. Grażyna Malukiewicz
2 Zakład Optometrii Wydziału Lekarskiego Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu
Kierownik: dr hab. n. med. Bartłomiej Kałużny


Summary: 

Purpose: The aim of our study is to present results of low vision patients treatment with aflibercept in Drug Prescription Program “Treatment of Neovascular (Exudative) Form of Age-related Macular Degeneration”.

Material and methods: 53 patients with exudative form of age-related macular degeneration and visual acuity 0.1–0.2 on the Snellen charts were enrolled. Group 01 consisted of 21 patients (12 women, 9 men), aged 76.1 ± 8.18 years, with vision acuity 0.1 and Group 02 – 32 patients (21 women, 11 men), aged 75.84 ± 8.24 years, with vision acuity 0.2. All patients were followed-up continuously with visual acuity charts, slit lamp examination and optical coherence tomography imaging.

Results: We observed improvement of the visual acuity in 61.9% patients of Group 01 and 53.13% patients of Group 02. We noticed that deterioration of vision was more often in Group 01 – 38.1% than in Group 02 – 28.12%. Mean central retinal thickness decreased in both groups, totally from 540.91 ± 129.83 μm to 395.47 ± 163.34 μm. 42.86% patients of Group 01 and 40.63% patients of Group 02 fulfilled exclusion criteria and the authors decided to terminate the therapy in Drug Prescription Program.

Conclusions: Low vision acuity during enrollment shouldn’t be the only factor which decides about disqualification to the therapy in Drug Prescription Program. Treatment of patients with low vision can be associated with faster decision about exclusion from Program.